In addition, targeting indoleamine 2,3-dioxygenase (IDO) released from tumor-associated MSCs can also effectively restore the infiltration of CD8+ T cells and B cells and enhance the efficacy of ICI therapy [83]. Here, CD8A is linked to neoplasm.